117 Summary and general discussion interaction of two or more interventions. Hence, in the field of rare neurological conditions, there are still many areas of clinical practice where scientific evidence is lacking or contradicting; a situation that is not expected to change in the near future since rehabilitation research funds are notoriously hard to obtain for rare diseases. It is therefore essential to acknowledge that guidelines for clinical management in HSP cannot solely be based on scientific evidence, but should also rely on professional experience, patients’ experiences and needs, and on mutual consensus. Consensus-based guidelines should be developed by a multidisciplinary, preferably international panel of experts and strive for recommendations agreed upon by the majority of experts. Unfortunately, until now, such guidelines do not yet exist for HSP. In order to fill this gap, I will be involved in developing consensusbased rehabilitation guidelines in collaboration with the European Reference Network of Rare Neurological Conditions (ERN-RND). The ERN-RND is pre-eminent in the development of such multidisciplinary guidelines, and arranges multiple educational activities to share and implement such guidelines. In order to develop the guideline for people with HSP, the ICF will be used to classify the consequences of HSP both in children and adults with HSP. Based on these findings, an ICF core set will be developed with a practical guideline on how signs and symptoms, activity limitations, and participation restrictions can best be identified. This guideline will be validated through a DELPHI procedure and be finalized with the development of consensus-based recommendations. These recommendations will support healthcare providers in the clinical management of people with HSP. 7
RkJQdWJsaXNoZXIy MjY0ODMw